The relationship between the quantitative evaluation of thyroid bed uptake and the disappearance of accumulation in adjuvant radioactive iodine therapy for differentiated thyroid cancer

被引:8
|
作者
Konishi, Kenta [1 ]
Ishiba, Ryo [1 ]
Ikenohira, Tsutomu [1 ]
Asao, Tomoyuki [1 ]
Hirata, Masanori [1 ]
Ohira, Keiichi [1 ]
Komatsu, Tetsuya [1 ]
Sawada, Michifumi [2 ]
Tanahashi, Yukichi [3 ]
Goshima, Satoshi [3 ]
Magata, Yasuhiro [4 ]
Nakamura, Katsumasa [1 ]
机构
[1] Hamamatsu Univ Sch Med, Dept Radiat Oncol, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka, Japan
[2] Hamamatsu Univ Sch Med, Dept Radiol, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka, Japan
[3] Hamamatsu Univ Sch Med, Dept Diagnost Radiol & Nucl Med, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka, Japan
[4] Hamamatsu Univ Sch Med, Preeminent Med Photon Educ & Res Ctr, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka, Japan
关键词
Thyroid cancer; Radioactive iodine therapy; Adjuvant therapy; Quantitative evaluation; Absolute radioactivity concentration; CARCINOMA; ABLATION;
D O I
10.1007/s12149-020-01546-8
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective Iodine-131 (I-131) radioactive iodine therapy (RAI) after total thyroidectomy is the standard treatment for patients with differentiated thyroid cancer (DTC). We investigated the relationship between the quantitative parameters of the iodine uptake and the disappearance of the accumulation in the thyroid bed in adjuvant therapy using a 1.11 GBq or 3.70 GBq dose of I-131. Methods We retrospectively analyzed the cases of 40 patients with DTC who were treated with RAI at our institution between April 2017 and August 2019. The patients were treated with the I-131 dose of 1.11 GBq (n = 25) or 3.70 GBq (n = 15) after total thyroidectomy. The I-131 whole-body scan and hybrid single-photon emission computed tomography/X-ray computed tomography (SPECT/CT) were performed 3 days after RAI. Using image analysis software, we measured the standardized uptake value (SUV) and absolute radioactivity concentration (kBq/ml) on the target lesions with the highest uptake in the thyroid bed. Results The median period from RAI to the evaluation of the absence of uptake of the thyroid bed was 6.75 months. After RAI, uptake of the thyroid bed disappeared in 26 of the 40 patients. The disappearance rate was significantly higher in the 3.70 GBq group than in the 1.11 GBq group (86.7% vs. 52.0%, respectively; p = 0.029). However, there were no significant differences in the values of kBq/ml or SUV between the 1.11 GBq group and 3.70 GBq group. On the other hand, the group in which the uptake disappeared after RAI showed significantly higher kBq/ml max and kBq/ml mean values than the group in which the uptake did not disappear after RAI (p = 0.028, p = 0.032, respectively). The SUVmax and SUVmean also tended to be higher in the disappeared-uptake group than the not-disappeared-uptake group, but the differences were not significant (p = 0.166, p = 0.176, respectively). Conclusions The quantitative evaluation might be useful as one of the predictive indicators of the disappearance of the accumulation of radioactive iodine in the thyroid bed.
引用
收藏
页码:159 / 166
页数:8
相关论文
共 50 条
  • [41] Poorly differentiated thyroid carcinoma (PDTC) characteristics and the efficacy of radioactive iodine (RAI) therapy as an adjuvant treatment in a tertiary cancer care center
    Thiagarajan, Shivakumar
    Yousuf, Aamir
    Shetty, Ratan
    Dhar, Harsh
    Mathur, Yash
    Nair, Deepa
    Basu, Sandeep
    Patil, Asawari
    Kane, Shubadha
    Ghosh-Laskar, Sarbani
    Chaukar, Devendra
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2020, 277 (06) : 1807 - 1814
  • [42] Effect of Prophylactic Central Compartment Neck Dissection on Serum Thyroglobulin and Recommendations for Adjuvant Radioactive Iodine in Patients with Differentiated Thyroid Cancer
    Wang, Tracy S.
    Evans, Douglas B.
    Fareau, Gilbert G.
    Carroll, Ty
    Yen, Tina W.
    ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (13) : 4217 - 4222
  • [43] Association Between Excessive Urinary Iodine Excretion and Failure of Radioactive Iodine Thyroid Ablation in Patients with Papillary Thyroid Cancer
    Sohn, Seo Young
    Choi, Joon Young
    Jang, Hye Won
    Kim, Hye Jeong
    Jin, Sang Man
    Kim, Se Won
    Suh, Sunghwan
    Hur, Kyu Yeon
    Kim, Jae Hyeon
    Chung, Jae Hoon
    Kim, Sun Wook
    THYROID, 2013, 23 (06) : 741 - 747
  • [44] Radioactive Iodine Therapy in Differentiated Thyroid Cancer: An Update on Dose Recommendations and Risk of Secondary Primary Malignancies
    Nguyen, Nghi C.
    Anigati, Elena M.
    Desai, Neil B.
    Oz, Orhan K.
    SEMINARS IN NUCLEAR MEDICINE, 2024, 54 (04) : 488 - 496
  • [45] Clinical Significance of Diffuse Hepatic Visualization and Thyroid Bed Uptake on Post-Ablative Iodine-131 Whole Body Scan in Differentiated Thyroid Cancer
    Kim, Keunyoung
    Kim, Seong-Jang
    Kim, In-Joo
    Kim, Yong-Ki
    Kim, Bum Soo
    Pak, Kyoungjune
    ONKOLOGIE, 2012, 35 (03): : 82 - 86
  • [46] Prediction of radioactive iodine remnant ablation failure in patients with differentiated thyroid cancer: A cohort study of 740 patients
    Prpic, Marin
    Kust, Davor
    Kruljac, Ivan
    Kirigin, Lora Stanka
    Jukic, Tomislav
    Dabelic, Nina
    Bolanca, Ante
    Kusic, Zvonko
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2017, 39 (01): : 109 - 115
  • [47] The utility of low-iodine diet in preparation for thyroid cancer therapy with radioactive iodine-A cohort study
    Luo, Hongxiu
    Tobey, Andrew
    Auh, Sungyoung
    Cochran, Craig
    Behairy, Noha
    Merino, Maria
    Zemskova, Marina
    Klubo-Gwiezdzinska, Joanna
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [48] Radioactive iodine-refractory differentiated thyroid cancer: an uncommon but challenging situation
    Schmidt, Angelica
    Iglesias, Laura
    Klain, Michele
    Pitoia, Fabian
    Schlumberger, Martin J.
    ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2017, 61 (01): : 81 - 89
  • [49] Update on the systemic management of radioactive iodine refractory differentiated thyroid cancer (Review)
    Babu, Geethu
    Kainickal, Cessal Thommachan
    MOLECULAR AND CLINICAL ONCOLOGY, 2021, 14 (02) : 1 - 7
  • [50] EVOLVING APPROACHES IN MANAGING RADIOACTIVE IODINE-REFRACTORY DIFFERENTIATED THYROID CANCER
    Sacks, Wendy
    Braunstein, Glenn D.
    ENDOCRINE PRACTICE, 2014, 20 (03) : 263 - 275